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Abstract
Background: Bacterial pneumonia in goats is usually caused by Mannheimia haemolytica and Pasteurella multocida.
Another important infection disease in lactating goats is intramammary infection producing mastitis, usually
associated with coagulase-negative Staphylococcus spp. However, treatment of bacterial pneumonia in goats not
affected by mastitis problems should be restricted to antimicrobials with scant penetration to milk in order to avoid
long withdrawal times. Ceftiofur is a third-generation cephalosporin antimicrobial with activity against various gram-
positive and gram-negative, aerobic and anaerobic bacteria encountered by domestic animals. The objectives of
the present study were to establish the serum concentration–time profile for ceftiofur in lactating goats after
intravenous, subcutaneous and a SC-long-acting ceftiofur formulation; to determine ceftiofur penetration into milk;
to determine in vitro and ex vivo activity of ceftiofur establishing MIC, MBC, MPC and time-kill profiles against field
strains of M. haemolytica and finally to calculate the main surrogate markers of efficacy.
Results: The pharmacokinetics studies revealed an optimal PK properties for the SC-LA formulation tested. Ceftiofur
was well absorbed following SC and SC-LA administration, with absolute bioavailabilities (F) of 85.16 and 84.43 %,
respectively. After ceftiofur analysis from milk samples, no concentrations were found at any sampling time. The
MIC, MBC and MPC data of ceftiofur against five M. haemolytica strains isolated from goats affected by pneumonia
were tested showing excelent sensitivity of ceftiofur against this pathogen. For PK-PD analysis, ratios were
calculated suggesting a high level of bacterial kill against the five strains of M. haemolytica tested.
Conclusions: The systemic ceftiofur exposure achieved in lactating goats following IV, SC and especially with the
SC-LA administration is consistent with the predicted PK-PD ratios needed for a positive therapeutic outcome for M.
haemolytica. Subcutaneous administration of the long-acting formulation showed safety and tolerance for all the
animals used. Ceftiofur concentrations exceeded the MIC and MBC for up to 72 h and MPC for up 32 h in serum.
Thus, this drug could be effective in treating infectious diseases of goats caused by M. haemolytica at a dose of
6 mg/kg with the SC-LA formulation.
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Background
Ceftiofur is a third-generation cephalosporin antimicro-
bial with activity against various gram-positive and
gram-negative, aerobic and anaerobic bacteria encoun-
tered by domestic animals [1]. As with all cephalospo-
rins, it is considered bactericidal because it inhibits
bacterial cell wall synthesis and its pharmacokinetic and
pharmacodynamic (PK ⁄ PD) parameter most associated
with efficacy is the time above a threshold concentration,
typically the MIC [2].
Over the past years, the food and milk that goats pro-
vide have become more popular in Europe and in the
United States [3]. Bacterial pneumonia are frecuent in
this species, and the most common bacterial isolates
from lungs of goats affected by pneumonia are Pasteur-
ella multocida and Mannhemimia haemolytica [3, 4].
Another important infection disease in lactating goats is
intramammary infection producing mastitis, usually as-
sociated with coagulase-negative Staphylococcus spp.
However, treatment of bacterial pneumonia in goats not
affected by mastitis problems should be restricted to an-
timicrobials with scant penetration to milk in order to
avoid long withdrawal times. Other antimicrobials agents
that could be used in pneumonia are fluoroquinolones
and macrolides that have a wide milk penetration.
Ceftiofur has been synthesized in various salt forms.
The sodium and hydrochloride salts were first developed
and approved worldwide for treatment of respiratory
disease in beef and dairy cattle. Additional indications
were also approved in swine, goats, sheep, horses, day-
old chickens, day-old turkey poults and dogs [5]. The
third salt approved was a ceftiofur free acid form in a
sterile oil formulation (CCFA) showing excellent
sustained-release properties. This oily, non-aqueous sus-
pension of CCFA has good efficacy and has been studied
in different animal species like horses [6], cattle [5], lac-
tating and non-lactating goats [3]. However, issues with
residues, inflammatory reactions and pain at the injec-
tion site have been reported.
In the present study, we have assayed a subcutane-
ous, aqueous, polymeric sustained-release formulation
with the sodium salt. This subcutaneous long-acting
formulation has been made with polymer P407. P407
is a block of copolymers contains 7 % polyoxyethy-
lene units and 30 % polyoxypropylene units. This
polymer has some advantages as its low toxicity, ex-
cellent compatibility with other chemicals and a high
solubilizing capacity for different drugs. P407 shows
temperature-dependent gelation (gel consistency at
37 °C and liquid consistency at 4 °C) [7]. The P407
gel has been evaluated for the delivery of biologically
active proteins such urease and interleukin-2 [8, 9]
and antibiotics as ceftiofur [7], doxycycline [10], mox-
ifloxacin [11] and difloxacin [12].
The objectives of the present study were: (1) to estab-
lish the serum concentration–time profile and to derive
pharmacokinetics data for ceftiofur in lactating goats
after intravenous (IV), subcutaneous (SC) and a subcuta-
neous long-acting (SC-LA) ceftiofur formulation; (2) to
determine the rate and extent of ceftiofur penetration
into and elimination from milk after IV, SC and SC-LA
administration of ceftiofur; (3) to determine in vitro ac-
tivity of ceftiofur establishing MIC and MBC in serum
and Mueller Hinton broth, and MPC of ceftiofur for five
strains of Mannheimia haemolytica isolated from cap-
rine (4) to determine ex vivo time-kill profiles of ceftio-
fur against the five strains of M. haemolytica in both in
serum and Mueller-Hinton broth (5) to calculate the
surrogate markers of efficacy against Mannheimia




Six clinically healthy Murciano-Granadina female lactat-
ing goats weighing between 40.5 and 56 kg and aged
from 2.5 to 3.5 years from the Caprine Farm of the Uni-
versity of Murcia were used. The animals were housed
and fed an antibiotic-free diet for at least 30 days pre-
ceding the study. For each treatment period of the
cross-over study, they were observed daily for general
health, and clinical observations were made prior to in-
jection and at 2, 10 and 24 h post-injection. Alfalfa hay
and water was provided ad libitum together with a
drug-free concentrate. The study was approved by the
Bioethics Committee of the University of Murcia.
Experimental design
A cross-over design (2 × 2 × 2) was used in three phases.
Each animal received either a single IV or SC injection
of ceftiofur sodium (Excenell® 4 g, Pfizer, Madrid, Spain)
at a dose of 2.2 mg/kg or a SC-LA administration of
6.6 mg/kg with at least a 15-day washout period.
For the IV administration, the solution was injected
into the left jugular vein and blood samples (4 mL) were
collected from the contralateral jugular vein. SC and SC-
LA injections were administered under the skin of the
back at a single location in the thoraco-lumbar region
lateral of the mid-line. Blood samples were collected at 0
(pre-treatment), 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 4,
6, 8, 10, 12, 24, 32, 48, 72, 96 and 120 h post-dosing.
Samples were centrifuged at 1500 g for 15 min and the
serum taken and stored at −90 °C until assayed.
Milk samples for analysis were collected from each
goat after complete evacuation of the udder by manual
stripping of each gland immediately before dosing on
the day of treatment administration (time 0) and at 1, 2,
4, 6, 8, 10, 12, 24, 32, 48, 72, 96 and 120 h after
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administration. After shaking the milk to homogenize, a
4–5 mL sample was collected and stored at −90 °C until
assayed.
Gel preparation
Gel was prepared on a weight basis using the cold
method [13]. Concentrations of P407 and ceftiofur re-
ported here are expressed as weight percentage (% wt/
wt). An amount of P407 sufficient to yield 25 % and Car-
boxymethylcellulose sodium to yield 2 % gel was slowly
added at 4 °C and ceftiofur sodium sufficient to yield a
20 % concentration was dissolved in the cold solution.
Analytical method
Serum and milk samples were analyzed for concentrations
of ceftiofur, desfuroylceftiofur, and related metabolites by
reduction and derivatization to desfuroylceftiofuraceta-
mide (DCA) [14]. Ceftiofur and desfuroylceftiofur-related
metabolites were extracted from serum and milk following
a reduction step through the addition of 1,4-dithioerythri-
tol solution (20 mg/mL in 0.1 M ammonium acetate, pH
= 8.9). An internal standard consisting of a cefotaxime so-
lution (200 μg/mL) was incorporated in this step. Follow-
ing a 30-min incubation step at 50 °C to fully reduce the
thioester bond in ceftiofur and desfuroylceftiofur-related
metabolites, the resulting desfuroylceftiofur was captured
on a C18 solid-phase extraction columns (Oasis HLB SPE
cartridges, Waters, Barcelona, Spain) and further deriva-
tized with iodoacetamide to create desfuroylacetamide
(DCA). DCA was removed from the column with 30:70
acetonitrile: 0.01 M ammonium acetate with 0.1 %
trifluoroacetic acid providing a final injection equal to iso-
cratic HPLC conditions (15 % acetonitrile: 85 % 0.01 M
ammonium acetate (0.1 % trifluoroacetic acid)). The
HPLC separation was performed using a reverse-phase
Kinetex TM PFP C18 column (250 × 4.6 mm; 5 μm) with
an injection volume of 100 μL. Ultraviolet detector was set
at 240 nm.
Method validation
Quality controls were prepared from a pool of blank
goat serum or milk spiked with seven concentrations of
ceftiofur between 0.10 and 10 μg/mL. Serum and milk
aliquots were stored at −90 ° C until assay. Aliquots of
quality controls were extracted as above and 100 μL was
injected into the chromatographic system. Standard
curves were obtained by unweighted linear regression of
ceftiofur and cefotaxime peak areas versus known con-
centrations. Each point was established from an average
of five determinations. Correlations coefficients (r) were
>0.99 for calibration curves. The percentage recovery
was determined by comparing the peak areas of serum
and milk blank samples spiked with different amounts of
drug and treated as any samples, with the peak areas of
the same standards prepared in phosphate buffer. Each
point was established from an average of five determina-
tions. The mean percentage recoveries of ceftiofur from
serum and milk were 84.79 and 88.16 %, respectively.
The assay precision (R.S.D.) was assessed by expressing
the standard deviation of repeated measurements as a
percentage of the mean value. Serum intra-day precision
was estimated from six replicates of three standard sam-
ples used for calibration curves (R.S.D. < 5.83 %). Milk
intra-day precision was R.S.D. < 10.2 %. Inter-day preci-
sion was estimated from the analysis of standard samples
(serum or milk) on three separate days. Serum inter-day
obtained a R.S.D. < 4.91 %. Milk inter-day assay obtained
a R.S.D. < 6.54 %. The limit of quantification (LOQ) and
the limit of detection (LOD) for was 0.1 μg/mL for
serum and milk.
Bacterial strains, MIC, MBC and MPC determination
Five field strains of M. haemolytica isolated from goats
affected by pneumonia in Spain were used. The strains
were stored at −80 °C in a nutrient broth enriched with
15 % glycerol until assayed. The MIC of ceftiofur was
determined in goat serum and Mueller-Hinton broth
(MHB, Fluka analytical, Madrid, Spain) using the
microdilution method recommended by CLSI [15]. The
assay was performed in U-bottomed, 96-well, custom-
designed microtiter plates. After overnight incubation at
37 °C on tryptone soya blood agar plates, bacterial sus-
pensions equal to a 0.5 McFarland standard were further
diluted and 10 μL were added to the plates to achieve a
final inoculum of 5 × 105 CFU/mL. The plates contained
antimicrobial dilutions ranging from 0.03 to 128 μg/mL
in 90 μL/well of goat serum or MHB, the final volume
was 100 μL. Assays were incubated at 37 °C and ob-
served after 24 h. The MIC was taken as the lowest drug
concentration that inhibited visible growth. MBC was
established by plate count as the concentration of anti-
bacterial to reduce a 3log10 (99.9 % killing) the initial in-
oculum, in accordance with CLSI guidelines [15].
The MPC was measured by agar dilution using a
method previously described [16]. Briefly, the content of
overnight cultures of each strain of M. haemolytica (5
plate per isolate) in TSBA was transferred to 100 mL of
MHB and incubated overnight at 37 °C with shaking at
200 rpm. The next day, bacterial suspensions were esti-
mated to have concentrations close to 3 · 108 CFU/mL
by turbidity measurements. Then, cultures were concen-
trated by centrifugation at 5000 g for 30 min at 5 °C and
re-suspended in 3 mL of fresh MHB. Aliquots of 200 μL
containing 1010 CFU were inoculated in TSBA plates
previously prepared with ceftiofur over a range from
0.03 to 128 μg/mL. Plates were incubated for 48 h at
37 °C and screened visually each 24 h for growth. The
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MPC was recorder as the lowest concentration that pre-
vented the growth of colonies.
For MIC, MBC and MPC assays, a non-inoculated plate
was included as a negative control, and an inoculated plate
without drug as a positive control. Also, S. aureus ATCC
29213 and E. coli ATCC 25922 strains were used as con-
trols. All determinations were performed in duplicate, and
the geometric mean was calculated.
In vitro antimicrobial growth (time-kill) curves
Time kill curves were obtained in a second trial after
MIC, MBC and MPC determination. In vitro and ex vivo
activity of ceftiofur against M. haemolytica was obtained
using a method previously described [17]. Eight to 10
colonies from overnight cultures in TSBA of each strain
were used to inoculate 9 mL of MHB and incubated
overnight at 37 °C with shaking at 200 rpm.
For in vitro assays, 480 μL of MHB or goat serum
were spiked with 10 μL of concentrated solutions of cef-
tiofur. The final samples contained antimicrobial con-
centrations at 0 (control), 0.25, 0.5, 1, 2, 4, 8 and 16
multiples of MIC previously obtained in each fluid. A
total of 10 μL of stationary-phase bacterial culture was
added to give a final concentration of approximately 5 ·
106 CFU/ml. Aliquots of 25 μL were sampled from each
culture at 0, 1, 2, 4, 8 and 24 h. Counts were determined
by serial dilution in saline and spread on TSBA agar
plates [18]. For ex vivo testing, serum samples from goat
which had received ceftiofur IV, SC or SC-LA at 2.2 or
6.6 mg/kg respectively, were collected at 0, 1, 2, 4, 12,
24, 32, 48, and 72 h. Concentrations of ceftiofur in these
samples were previously determined with the HPLC
method described in the above section. Then, a total of
10 μL of stationary-phase bacterial culture was added,
and aliquots of 25 μL were sampled from each culture at
0, 1, 2, 4, 8 and 24 h using the same methodology de-
scribed for in vitro time kill curves. Counts were deter-
mined by serial dilution in saline and spread on TSBA
agar plates. The lower limit of detection was 40 CFU/
mL for both in vivo and ex vivo assays. Time kill curves
were performed at 37 °C with shaking at 200 r.p.m.
Pharmacokinetic analysis
The serum ceftiofur time-concentration data were ana-
lysed by non-compartment methods using WinNonLin
5.2 (Pharsight Corp, Mountain View, Calif ). The area
under the concentration-time Curve (AUC) was calcu-
lated using the linear trapezoidal rule with extrapolation
to time infinity. Mean Residence Time was calculated as
MRT =AUMC/AUC. Mean absorption times were cal-
culated as MAT =MRTSC, SC-LA – MRTIV and Ka was
calculated non-compartment methods as Ka = 1/MAT.
The systemic clearance was estimated as Cl = Dose/
AUC. The apparent volume of distribution at steady
state were calculated as Vss = (Dose · AUMC)/AUC
2. The
apparent volume of distribution (area method) was cal-
culated as Vz = Dose/ (AUC · λz). Biovailability (F) was
calculated by the method of corresponding areas:
F %ð Þ ¼ AUCSC; SC‐LA DoseIV
  100 = AUCIV DoseSC; SC‐LA
  
Statistical analysis
Descriptive statistical parameters as mean, standard de-
viation and coefficient of variation were calculated. Har-
monic means were calculated for the half-lives of
elimination. A Kruskal-Wallis analysis of variance,
followed by a Dunn multiple comparison test if applic-
able was used to test parameters for significant differ-
ences between IV, SC and SC-LA administration. Dose-
dependent (AUC and Cmax) parameters were corrected
with dose to test for statistical differences. The level of
significance was P ≤ 0.05. The statistical software used
was SPSS (IBM SPSS Statistics, Version 19.0. Armonk,
NY: IBM Corp).
Results
The mean (±SD) serum concentrations of ceftiofur fol-
lowing IV, SC and SC-LA administration are plotted in
Fig. 1. The estimates of the non-compartmental pharma-
cokinetics parameters following IV, SC and SC-LA ad-
ministration are summarized in Table 1.
Clinical examination of all goats after each phase of
the trial did not reveal any abnormalities. Local or sys-
temic adverse reactions were not observed neither dur-
ing nor after IV, SC and SC-LA administration,
respectively.
The ceftiofur half-life (t½λz) for IV, SC and SC-LA
routes was 4.21, 5.10 and 41.12 h. Clearance value after
IV dosing was 0.04 ± 0.01 L/kg•h. After SC and SC-LA
administration, the absolute bioavailability was mean
(±S.D) 85.16 ± 10.24 % and 84.43 ± 7.40 %, respectively.
The Cmax was 6.25 ± 0.85 μg/mL (SC) and 4.26 ±
0.68 μg/mL (SC-LA) with a Tmax of 0.91 h (SC) and
4.66 h (SC-LA). There were no significant differences
between values calculated for Cmax, AUC0-∞ and AUC0–
24 for both subcutaneous routes of administration (dose
corrected for comparison). However, significant differ-
ences (P < 0.05) were found between SC and SC-LA for-
mulations for λz, t1/2λz, MRT, MAT, Ka and Tmax as
expected.
After ceftiofur analysis from milk samples, no concen-
trations were found at any sampling time.
The MIC, MBC and MPC values were obtained from
strains of M. haemolytica isolated from goats affected by
pneumonia. Ceftiofur showed excellent in vitro activity,
the surrogate markers were calculated and are shown in
Table 2. Time-kill curves in serum and Mueller-Hinton
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broth are shown in Fig. 2. Time-kill curves in goat
serum after SC and SC-LA administration of ceftiofur
are shown in Fig. 3.
Discussion
The pharmacokinetics of ceftiofur sodium has been
studied in goats [19], sheep [20], camels [21], llamas
[22], deers [23], horses [6], fouls [14] and pigs [24].
However, there are limited data available in lactating
animals and especially in small ruminants like lactating
goats. Besides, to our knowledge there is no information
about ceftiofur pharmacokinetics and pharmacodynamics
integration data of the main pathogens involve in pneumo-
nia in goats (Pasteurella multocida and Mannheimia
haemolytica) and studies with long-acting formulations are
very limited [7, 11, 12]. Some years after ceftiofur sodium
development and commercial availability, a new sustained-
release ceftiofur salt was developed as crystalline-free acid
Fig. 1 Semilogarithmic plot of serum concentrations (mean ± SD) of ceftiofur and desfuroylceftiofur-related metabolites after IV administration
(2.2 mg/kg) (IV; -●-), SC administration (2.2 mg/kg) (SC; -○-), and SC-LA administration (6.6 mg/kg) (SC-LA; -□-) in goats (n = 6)
Table 1 Pharmacokinetic parameters (mean ± S.D.) of ceftiofur in lactating goats after IV and SC administration at a dose of 2.2 mg/
kg bodyweight, and after SC-LA administration at a dose of 6.6 mg/kg bodyweight (n = 6)
Treatment
Parameters Intravenous SC SC-LA
λ z (1/h) 0.16 ± 0.07 0.14 ± 0.06 0.02 ± 0.01 a, b
t½λz
1 (h) 4.21 5.10 41.12a, b
Vss (L/kg) 0.18 ± 0.05 – –
Vz (L/kg) 0.31 ± 0.14 – –
AUC0–24 (μg · h/mL) 45.51 ± 6.80 38.17 ± 6.97 85.13 ± 7.53 a
AUC0-∞ (μg · h/mL) 47.06 ± 6.84 39.88 ± 6.26 117.12 ± 11.54 a
MRT (h) 4.27 ± 0.98 6.29 ± 0.35a 25.11 ± 4.35 a, b
Cl (L/h · kg) 0.04 ± 0.01 – –
MAT (h) – 2.02 ± 1.09 20.83 ± 5.13 b
Ka (1/h) – 0.53 ± 0.49 0.03 ± 0.01
b
Cmax (μg/L) – 6.25 ± 0.85 7.77 ± 1.26
Tmax (h) – 0.91 ± 0.20 4.66 ± 2.05
b
F (%) – 85.16 ± 10.24 84.43 ± 7.40
T½λz: The elimination half-life associated with the terminal slope (λz) of a semilogarithmic concentration-time curve. Vz: The apparent volume of distribution calculated
by the area method. Vss: The apparent volume of distribution at steady state. AUC0-∞: The area under the serum concentration-time curve from zero to infinity. AUC0–24:
the area under the serum concentration–time curve from zero to 24 h. MRT: Mean residence time. MAT: Mean absorption time. Cl: The total body clearance of
drug. Tmax: The time to reach peak concentration following extravascular administration. MAT: Mean absorption time. Ka: Absorption rate constant. Cmax:
The peak concentration following extravascular administration. F: The fraction of the administered dose systemically available (bioavailability). aSignificantly different
from IV (P < 0.05). bSignificantly different from SC (P < 0.05). 1 Harmonic Mean
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(CCFA). The long-acting formulation has been studied in
different animal species as horses [6], cattle [5], lactating
and non-lactating goats [3]. Importance of development of
sustained-release formulations in veterinary medicine and
especially in food animal species has been increasing last
years. The advantages of long-acting formulations of ceftio-
fur (and other drugs) in lactating goats include less quantity
of drug used (decreasing collateral effects and accumulation
in long-term treatments), increased treatment efficacy (less
fluctuations of the stationary concentrations and much lon-
ger release times) and a reduction in handling (stress of the
animals and veterinary costs are decreased). On the other
hand, it is necessary to consider drug safety, efficacy and
residues at the site of infection as serious issues with these
formulations. Although most studies have concluded that
ceftiofur free-acid in pigs and cattle was well tolerated
systemically, frecuent adverse effects have been reported at
the injection sites with the CCFA formulation. Other
formulations have been studied like liposomes in cows [25].
In the present study an aqueous polymeric sustained-
release formulation has been developed for subcutaneous
administration. After IV administration, the half-life (t½λz =
4.21 h) was slightly higher than that reported in lactating
goats after IV dosing of ceftiofur sodium (t½λz = 3.88 h)
[19], and clearance (Cl = 0.04 L/h · kg) was lower than the
data reported by the same authors (0.08 L/h · kg). The vol-
ume of distribution (0.31 and 0.18 L/kg calculated by the
area method (Vz) and at steady-state (Vss), respectively, sug-
gests limited penetration through biological membranes,
and these values indicate that ceftiofur is widely distributed
into the extravascular tissues. In other studies, larger but
also limited volume of distribution Vss was described for
ceftiofur sodium in lactating (0.31 L/kg) and non-lactating
(0.25 L/kg) goats [19]. Elimination half-life (t½λz) of the SC-
LA formulation (41.12 h) was far longer than that for the
SC administration (5.1 h) showing prolonged permanence
Fig. 2 In vitro antibacterial activity of ceftiofur in MHB (a) and serum (b) of goats against M. haemolytica expressed as mean values (n = 5). SD
values are excluded for clarity
Table 2 Surrogate markers of efficacy from pharmacokinetics parameters after IV, SC and SC-LA administraton of ceftiofur, calculated
for a mean MIC, MBC and MPC of ceftiofur on M. haemolytica strains isolated from goats (n = 5)
Parameter IV SC SC-LA
Mean MIC (M. haemolytica) = 0.0436 μg/mL
Cmax/MIC – 130.53 ± 28.65 145.47 ± 22.55
AUC0-∞/MIC (h) 1079.16 ± 157 914.77 ± 143 2686.34 ± 264
AUC24/MIC (h) 1043.80 ± 155 875.38 ± 160 1952.44 ± 173
T >MIC (h) 24 h 24 h 72 h
Mean MBC (M. haemolytica) = 0.10 μg/mL
Cmax/MBC – 56.91 ± 12.49 63.42 ± 9.83
AUC0-∞/MBC (h) 470.51 ± 68.46 398.84 ± 62.60 1171.24 ± 115.4
AUC24/MBC (h) 455.1 ± 67.98 381.66 ± 69.78 851.27 ± 75.36
T >MBC (h) 24 h 24 h 72 h
Mean MPC (M. haemolytica) = 0.55 μg/mL
Cmax/MPC – 10.34 ± 2.27 11.53 ± 1.79
AUC0-∞/MPC (h) 85.54 ± 12.36 72.51 ± 11.38 212.95 ± 20.98
AUC24/MPC (h) 82.74 ± 12.36 69.39 ± 12.69 154.77 ± 13.70
T >MPC (h) 12 h 12 h 32 h
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of the drug in serum with this long-acting formulation. Cef-
tiofur was well absorbed following SC and SC-LA adminis-
tration, with absolute bioavailabilities (F) of 85.16 and
84.43 %, respectively. MAT was 2.02 h for the SC adminis-
tration and ten-fold longer for the SC-LA formulation
(20.83 h). Absorption rate constant (Ka) was 0.53 h
−1 for
the SC administration and 0.03 h−1 after SC-LA. These ab-
sorption data reflect that the polymeric formulation has re-
duced considerably the rate of absorption affecting the
elimination rate where the SC-LA formulation showed a
significantly longer elimination half-life respect to the con-
ventional SC formulation.
After ceftiofur analysis from milk samples, no concen-
trations were found at any sampling time. This result is
in agreement with other studies in goats [3] and cows
[26]. Ceftiofur sodium has a pKa value of 3.7. Ceftiofur
sodium in the blood stream (pH 7.4) would act as a
weak acid with and insufficient lipid-soluble properties
at this pH to penetrate milk, which can also explain lim-
ited volume of distribution obtained.
Pharmacodynamics of ceftiofur against M. haemoly-
tica in MHB showed in vitro maximum growths from
3.5°109 to 7°109 CFU/mL obtained at 24 h without
drug. Ceftiofur concentrations multiples to 1 ×MIC
produced a 0log10 reduction in count over 24 h (bac-
teriostatic effect), whereas concentrations less than
1 ×MIC produced no growth inhibition (Fig. 2a). A
3-4log10 reduction of count was achieved after 24 h
from 2 ×MIC (bactericidal effect). After in vitro time
kill curves in serum, maximum growths from 4.4°109
to 8.5°109 CFU/mL were obtained at 24 h without
drug. Concentrations less than or equal to 2 ×MIC
produced no growth inhibition with a 0-2log10 reduc-
tion in count over 24 h. A 3-4log10 reduction was
achieved at concentrations similar or higher than 4 ×
MIC after 24 h of incubation, and a regrowth was
not observed (Fig. 2b).
Ex vivo time kill curves showed antibacterial activity of
ceftiofur against M. haemolytica in serum of lactating
goats administered as a conventional SC and SC-LA for-
mulation. The time points selected for the study with
serum samples were of 0 (control), 1, 2, 4, 12, 24, 32, 48
and 72 h after drug administration. Maximum growths
closed to 5°109 CFU/mL were obtained at 24 h without
drug. For SC time kill curve (Fig. 3a), a 3-4log10 reduc-
tion after 24 h incubation was achieved with ceftiofur
samples obtained from 1 to 24 h. A 2 log10 reduction
was observed with at samples measured at 32 h. How-
ever serum samples from 48 to 72 h produced no
growth inhibition, whereas these time points achieved a
3log10 reduction after 24 h of incubation with the SC-
LA formulation. Moreover, samples between 1 and 32 h
produced an elimination of organisms from 8 to 24 h of
incubation with a 4-5log10 reduction. These results
could be explained by the ceftiofur concentrations
achieved with the SC-LA formulation.
The most important factor determining the efficacy of
β-lactam antimicrobials such as ceftiofur is the amount
of time that serum concentrations exceed the MIC of a
given pathogen [27, 28]. However, this approach, almost
unanimous in literature, is been questioned in some
cases. In a recent PK/PD study of a depot formulation of
amoxicillin in calves against bovine respiratory pa-
thogens, Mannheimia haemolytica and Pasteurella
multocida, it was stated that for sustained-release for-
mulations a concentration-dependent action would bet-
ter fit according to the time-kill data obtained [29].
Similar results were found in sheep against Mannheimia
haemolytica and Pasteurella multocida isolates for
amoxicillin [30]. Additionally, it has been reported that
for drugs like the β-lactams, where efficacy has been
found to be correlated to the T >MIC, the best PK/PD
index shifts towards AUC/MIC dependence as half-life
increases [31]. In the present study, in vitro and ex vivo
Fig. 3 Ex vivo antibacterial activity of ceftiofur from 1 to 72 h in (a) goat serum after SC administration at a dose of 2.2 mg/kg bodyweight, and
(b) goat serum after SC-LA administration at a dose of 6.6 mg/kg bodyweight against M. haemolytica, values are mean (n = 5). SD values are ex-
cluded for clarity
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time-kill curves against Mannheimia haemolytica also
suggest a possible concentration-dependent action. There-
fore, the modelling of AUC/MIC data as surrogate for/
predictor of efficacy is justified at least for these respira-
tory tract pathogens [32, 33]. The longer half-life obtained
in the present study for the SC-LA formulation (41.12 h)
regard to the SC (5.1 h) reinforce this approach for PK/PD
integration of our data. Thus, PK/PD integration was cal-
culated for the five strains of M. haemolytica using the
three commonly used surrogates markers of efficacy,
AUC/MIC, Cmax/MIC and T >MIC, required to inhibit
growth.
The MIC, MBC and MPC data of ceftiofur against five
M. haemolytica strains isolated from goats affected by
pneumonia were tested. The MIC values in this study
showed good sensitivity of ceftiofur against this pathogen.
MIC, MBC and MPC are values tested in in vitro condi-
tions, and it is known influence of matrix when MIC and
MBC values are calculated (MHB and serum) mainly by ef-
fect of drug protein binding that should correspond to
lower MIC and MBC values in MHB regard to serum
values. In our study no differences were found in MIC
values between both matrices. However in the case of MBC
values calculated both in MHB and serum, differences were
found in two strains (two-fold) between MHB and serum
which is in agreement with the lower total protein concen-
trations present in MHB respect to serum [34].
On the other hand, although MIC values are the
standard to calculate the three most important surrogate
markers of efficacy Cmax/MIC, AUC0–24/MIC ratios and
T >MIC to get an optimal dosage regimen, MIC values
are considered less appropriate in preventing the emer-
gence of resistant strains. The use of MPC values de-
fined as the lowest drug concentration that prevents the
growth of the least susceptible first-step resistant mu-
tants have been considered to calculated AUC24/MPC
ratios and the mutant selection window (MSW) that
serve as an indicator of drug exposure that prevents the
selection of drug-resistant mutant [35, 36]. In the
present study, AUC24/MPC ratio and T >MPC were cal-
culated and for the SC-LA formulation values of 154 h
and 32 h were obtained, respectively, showing the good
profile of the long-acting formulation to achieve both
clinical efficacy and prevention of emergence of resistant
strains. Besides, the MIC and MPC are also useful to de-
fine the bounds of the mutant selection window (MSW),
a range of antibacterial concentrations in which drug
least susceptible cells could be selected most frequently.
MSW in this study range from 0.0436 and 0.55 μg/mL
according to the mean MIC and MPC values. Concen-
trations of ceftiofur with the LA formulation exceed the
MPC for the first 48 h which suggest that susceptible
strains of M. haemolytica in vivo could be eradicated.
However, it is necessary to be cautious with these results
and to consider factors like in vitro conditions of MPC
calculation, lack of studies, scores of the clinical symp-
toms in affected animals and the low number of strains
tested in this study.
For PK-PD analysis, the MIC data of ceftiofur against
M. haemolytica strains isolated from goats affected by
pneumonia were tested resulting a mean MIC of
0.0436 μg/mL. The Cmax/MIC, AUC24/MIC, AUC0-
∞/MIC ratios and T >MIC were calculated (Table 2).
The four ratios used suggest a high level of bacterial kill
against the five strains of M. haemolytica tested. For the
SC-LA formulation AUC24/MIC, even AUC0-∞/MIC ex-
ceed widely 125 h, and Cmax/MIC exceed 10 as the ratios
usually considered to have clinical efficacy. T >MIC was
greater than 72 h for the SC-LA formulation. Although
these ratios should be integrated with MIC distribution
values from field isolates [29], these data show a high
clinical efficacy against this pathogen and possibly
against other pathogens in goats.
Conclusions
The systemic ceftiofur exposure achieved in lactating
goats following IV, SC and especially with the SC-LA ad-
ministration is consistent with the predicted PK-PD ra-
tios needed for a positive therapeutic outcome for M.
haemolytica. Subcutaneous administration of the long-
acting formulation showed safety and tolerance for all
the animals used. Milk penetration of ceftiofur was non-
existent in all animals at least at the limit of detection of
our study, which is a clear advantage in lactating animals
affected by pneumonia avoiding withdrawal periods.
This study has shown that ceftiofur concentrations
exceeded the MIC and MBC for up to 72 h and MPC
for up 32 h in serum. Thus, this drug could be effective
in treating infectious diseases of goats caused by M. hae-
molytica at a dose of 6 mg/kg with the SC-LA formula-
tion. However, further studies in affected animals taking
into account other factors as scores of the clinical symp-
toms, to optimize and to know the optimal ratios of the
surrogate markers of efficacy.
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